Forskning
Udskriv Udskriv
Switch language
Region Hovedstaden - en del af Københavns Universitetshospital
Udgivet

Clinical experience with eslicarbazepine acetate in adults with sub-analysis of elderly

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  1. Perisylvian epileptic network revisited

    Publikation: Bidrag til tidsskriftReviewForskningpeer review

  2. Chronic hyponatremia - Why care? A case report

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Visual field defects after temporal lobe resection for epilepsy

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  4. Unexpected marked seizure improvement in paediatric epilepsy surgery candidates

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  5. Do patients need to stay in bed all day in the Epilepsy Monitoring Unit? Safety data from a non-restrictive setting

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  1. Psychogenic nonepileptic seizures treated with psychotherapy: Long-term outcome on seizures and healthcare utilization

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. An explorative literature review of the multifactorial causes of osteoporosis in epilepsy

    Publikation: Bidrag til tidsskriftReviewForskningpeer review

  3. Hyponatremia and metabolic bone disease in patients with epilepsy: A cross-sectional study

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  4. Chronic hyponatremia - Why care? A case report

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

Vis graf over relationer

PURPOSE: Eslicarbazepine acetate (ESL) is indicated for treatment of focal epilepsy. Our aim was to evaluate the effect and tolerability of ESL in elderly and younger adults. The primary objective was to measure changes in seizure frequency before and after at least six months of treatment. Secondary objective was to analyse the safety profile. Sub-analysis was performed in patients previously treated with oxcarbamazepine.

METHOD: A single-centre, retrospective study of patients with focal epilepsy treated with ESL. Data were collected by reviewing the clinical and laboratory files. Seventy-two patients received ESL, of which 14 were ≥60 years old, and were analysed for adverse effects. Fifty-nine patients received treatment for ≥6 months and were included in the evaluation of seizure frequency; in this group 12 were ≥60 years old.

RESULTS: Seizure frequency (n=59) was reduced for both young adults (< 60years) and elderly adults (≥60); both groups achieved better seizure control from an average of 2 to 0.5 (p-value: 0.002) and 3.5 to 0.65 (p-value:<0.05) seizures per month, respectively. Adverse effects leading to treatment discontinuation (n=72) were more frequent in elderly (42.9%) than in young adults (17.2%) (p-value 0.04). There was no significant difference in mild adverse effects between young (15.5%) and elderly adults (14.3%). Most common adverse effects were somnolence, gastrointestinal disturbances and dizziness.

CONCLUSIONS: The study indicates that ESL has an advantageous profile in relation to seizure control. The discontinuation rate might be higher in elderly than in younger adults. Further prospective studies are needed to confirm these conclusions.

OriginalsprogEngelsk
TidsskriftSeizure
Vol/bind53
Sider (fra-til)94-99
Antal sider6
ISSN1059-1311
DOI
StatusUdgivet - 2017

ID: 52659782